Kano Therapeutics
Cambridge, Massachusetts, United StatesFounded 202114+ employeesPrivate
$7.1M raisedSeed· last: seed (Nov 2025)· 3 rounds
Backed by(6 investors)
Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them.
